Dullaart R P, van Doormaal J J, Hoogenberg K, Sluiter W J
Department of Endocrinology, University Hospital, Groningen, Netherlands.
Neth J Med. 1995 Apr;46(4):179-84. doi: 10.1016/0300-2977(94)00116-q.
Increases in plasma low-density-lipoprotein (LDL) cholesterol and apolipoprotein B (apo-B) are well known in primary hypothyroidism, but it is uncertain whether thyroid dysfunction is associated with elevated levels of the atherogenic lipoprotein (a) (Lp(a)).
The effect of short-term hypothyroidism on plasma Lp(a) was studied in 14 patients who had undergone a total thyroidectomy because of a well-differentiated thyroid carcinoma. They were studied 2 weeks after withdrawal of triiodothyronine (T3) therapy and 7 (5-9) weeks after resumption of T3 treatment (75-100 micrograms T3 daily). Fourteen euthyroid subjects served as controls.
In the hypothyroid phase the athyreotic patients had higher levels of Lp(a) (105 [12-536] vs. 42 [1-321] mg/l, p < 0.05), apo-B (p < 0.001) and LDL cholesterol (p < 0.001) as compared with the euthyroid control subjects. T3 therapy lowered Lp(a) by 29% to 50 (12-535) mg/l, p < 0.01. Apo B and LDL cholesterol fell by 42% (p < 0.001) and by 53% (p < 0.001), respectively. After resumption of T3 therapy the levels of Lp(a), apo-B and LDL cholesterol were not different from those of the control subjects. The mean percentual decreases in Lp(a) and in apo-B were similar, although the individual changes in Lp(a) were more variable.
Short-term hypothyroidism increases plasma Lp(a) and T3 therapy rapidly lowers Lp(a) together with apo-B and LDL cholesterol. Our findings support the hypothesis that thyroid hormone regulates plasma Lp(a) and apo-B in a parallel manner. Elevated concentrations of Lp(a) in combination with LDL cholesterol may be involved in the increased risk of cardiovascular disease assumed to be associated with hypothyroidism.
原发性甲状腺功能减退症患者血浆低密度脂蛋白(LDL)胆固醇和载脂蛋白B(apo-B)升高已为人熟知,但甲状腺功能障碍是否与致动脉粥样硬化脂蛋白(a)[Lp(a)]水平升高相关尚不确定。
对14例因分化型甲状腺癌接受甲状腺全切术的患者进行研究,观察短期甲状腺功能减退对血浆Lp(a)的影响。在停用三碘甲状腺原氨酸(T3)治疗2周后以及恢复T3治疗(每日75 - 100微克T3)7(5 - 9)周后对他们进行研究。14例甲状腺功能正常的受试者作为对照。
与甲状腺功能正常的对照受试者相比,甲状腺功能减退期无甲状腺患者的Lp(a)水平更高(105 [12 - 536] 对比 42 [1 - 321] 毫克/升,p < 0.05),apo-B(p < 0.001)和LDL胆固醇(p < 0.001)水平也更高。T3治疗使Lp(a)降低29%,降至50(12 - 535)毫克/升,p < 0.01。apo B和LDL胆固醇分别下降42%(p < 0.001)和53%(p < 0.001)。恢复T3治疗后,Lp(a)、apo-B和LDL胆固醇水平与对照受试者无异。Lp(a)和apo-B的平均百分比下降相似,尽管Lp(a)的个体变化更具变异性。
短期甲状腺功能减退会使血浆Lp(a)升高,T3治疗可使Lp(a)与apo-B和LDL胆固醇一起迅速降低。我们的研究结果支持甲状腺激素以平行方式调节血浆Lp(a)和apo-B这一假说。Lp(a)浓度升高与LDL胆固醇共同作用,可能会增加被认为与甲状腺功能减退相关的心血管疾病风险。